Our Research Collaboration with Lab Ofichem
As part of our continued synergistic work with world-leading organisations in the European medicinal cannabis industry, we are proud to confirm our collaborative research partnership with the Netherlands based Lab Ofichem, part of the Ofichem Group.
Working in conjunction with their R&D and Technical Innovation departments, and using their high quality APIs combined with our ground-breaking technology, we are developing novel, controlled slow-release formulations for administering cannabis based pharmaceutical medicines (CBPMs) with maximised medical benefit whilst eliminating the risk of exceeding the desired dosage.
These routes of administration — once proven to be effective, cost efficient and safe — will be used to deliver a genuine medical breakthrough in the UK, with major pharmaceutical implications for the cannabis industry around the world, leading to the creation of trusted new products that will pioneer the highest standards and quality whilst at the same time offering more affordable options to the patient.
Through this partnership we seek to drive forward medical innovations, establish the very highest quality standards in the medicinal cannabis industry and contribute meaningful and valuable research results.